Conjugates comprising cell-binding agents and cytotoxic agents
US-2016095938-A1 · Apr 7, 2016 · US
Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines
US11628223B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11628223-B2 |
| Application number | US-201816651501-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 28, 2018 |
| Priority date | Sep 29, 2017 |
| Publication date | Apr 18, 2023 |
| Grant date | Apr 18, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines represented by the [Formula 24], [Formula 25], [Formula 26], and/or [Formula 27].
First claim
Opening claim text (preview).
The invention claimed is: 1. An antibody-drug conjugate represented by [Formula 25], [Formula 26], [Formula 27], or [Formula 28], wherein: [Formula 28] is: wherein: m 2 represents 1 or 2; Ab represents an immunoglobulin G (IgG) antibody or a functional fragment of the immunoglobulin G (IgG) antibody; and the N297 glycan of Ab represents: (i) N297-(Fuc)MSG1 of [Formula 29], N297-(Fuc)MSG2 of [Formula 30], or N297-(Fuc)SG of [Formula 31]: wherein: L(PEG) represents —NH—CH 2 CH 2 —(OCH 2 CH 2 ) 3 —*, wherein the —NH— at the left end is bound via an amide bond to the carboxylic acid at the 2-position of a sialic acid at the non-reducing terminal in one or both of the 1-3 and 1-6 branched chains of the β-Man in the N297 glycan, and further wherein each * represents bonding to a nitrogen atom at the 1-position or 3-position of the triazolyl in [Formula 25], [Formula 26], [Formula 27], or [Formula 28]; and each represents bonding to Asn297 of the antibody; or (ii) a mixture of N297-(Fuc)MSG1 of [Formula 29] and N297-(Fuc)MSG2 of [Formula 30] above.
Assignees
Inventors
Classifications
Medicinal preparations containing materials or reaction products thereof with undetermined constitution · CPC title
- A61K47/68035Primary
the drug being a pyrrolobenzodiazepine · CPC title
Glycopeptides, glycoproteins · CPC title
Complementarity determining region [CDR] · CPC title
- A61K47/6803Primary
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11628223B2 cover?
- A novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines represented by the [Formula 24], [Formula 25], [Formula 26], and/or [Formula 27].
- Who is the assignee on this patent?
- Daiichi Sankyo Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K47/68035. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).